Phase I/II Master Protocol of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy (SMART)
Summary
This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer. The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer. Phase 2 will evaluate efficacy of SMART with specific reference to tumor control and improvement in patient reported outcome measures
General Information
NCT#: NCT04115254
Study ID: 19-353
Trial Phase: Phase I/II
Trial Sponsor: Dana-Farber Cancer Institute
Therapies Used in This Trial: Stereotactic body radiotherapy (SBRT)